# Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

> **NCT04765709** · PHASE2 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 10 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **COMBINATION_PRODUCT:** durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)
- **COMBINATION_PRODUCT:** Durvalumab plus radiotherapy
- **BIOLOGICAL:** durvalumab

## Key facts

- **NCT ID:** NCT04765709
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-24
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Low enrolment rate
- **Last updated:** 2025-12-16

## Collaborators

- AstraZeneca
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765709, "Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04765709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*